Product Images Donepezil

Donezepil Hydrochloride is available in tablet form with 10mg dosage strength. It is a prescription drug and comes in a pack of 100 tablets (10 x 10). The tablets are film-coated and must be stored between 20-25°C. The package belongs to manufacturer Camber Pharmaceuticals Inc. and is packaged by American Health Packaging. The product must be kept away from children. No further information is available in the text.*

This is a list of different formulations of the medication Donepezil with different doses and names. There is no additional information and thus, it is not possible to provide any further description.*

This is a description of a medication named Donepezil Hydrochloride which comes in the form of USP Tablets. This medicine comes in a pack of 100 tablets which is further divided into 10 sections, each section containing 10 tablets. The Film-Goated Tablet contains certain chemicals whose description is unclear due to the text. The dosage should be decided after reading the package insert carefully. The medicine should be stored at an optimal temperature of 20° to 25°C. The package has the details of the manufacturer and the packager of the product.*

This is a chart showing the cumulative percentage of patients who had a certain level of response based on treatment with Donepezil Hydrochloride or Placebo. Along with this, it also shows the change in ADAS cog for each treatment group. The chart is divided into different points in time and different dosages of medication.*

This appears to be a table of data related to changes from baseline in clinical improvement and decline for a drug treatment. The drug in question is Donepezil Hydrochloride at 10mg/day, and there is a comparison with a placebo. The table appears to show the mean (+SE) change from baseline for both the drug and placebo groups at different intervals of drug treatment. However, it is difficult to determine the full meaning without additional context.*

The text is a graph showing the cumulative percentage of patients who experienced a change in SIB (Severe Impairment Batter) from baseline after taking 10mg/day of donepezil hydrochloride compared to a placebo. There are no values or measurements provided for the Y-axis or X-axis.*

This is a table showing the percentage of patients exhibiting change in ADAS cog (Alzheimer's Disease Assessment Scale-cognitive subscale) based on their assigned treatment group after 1 year. The treatment groups include Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and Placebo. The table also shows the cumulative percentage of patients with no change in their condition.*

This appears to be a table showing the percentage of patients taking different dosages of Donepezil Hydrochloride and placebo, with an additional column titled "CIBIC-Plus Rating". However, some of the text is illegible due to errors.*

This is a report on the ADAS-cog (Alzheimer's Disease Assessment Scale - cognitive subscale) change from baseline using mean values and standard errors. The report shows the clinical improvement and decline in patients treated with donepezil hydrochloride at a dosage of 10mg per day relative to a placebo group. The report provides data for different time intervals after the start of treatment, measured in weeks.*